Search Results - "Shuttleworth, Stephen Joseph"

Design and Development of a Novel Orally-Active, PI3K-p110Beta/Delta Inhibitor with Combined Tumor Immunotherapeutic, Growth Inhibition and Anti-Metastatic Activity by Shuttleworth, Stephen Joseph

“…The phosphatidylinositide 3-kinases (PI3Ks) have emerged as important therapeutic targets for the treatment of hematological malignancies and solid tumors. In…”
Get full text

Abstract 2366: Targeting PI3 pathway in ibrutinib resistant diffuse large B-cell lymphoma by Jain, Neeraj, Sehgal, Lalit, Shuttleworth, Stephen Joseph, Samaniego, Felipe

“…Abstract Diffuse large B-cell lymphoma (DLBCL) is the most common subtype of non-Hodgkin lymphoma (NHL) and approximately 30% of patients with DLBCL develop…”
Get full text

Felipe Samaniego by Jain, Neeraj, Sehgal, Lalit, Davis, R. Eric, Shuttleworth, Stephen Joseph, Samaniego, Felipe

“…Background: Diffuse large B cell lymphoma (DLBCL) is the most common subtype of non-Hodgkin lymphoma (NHL) and approximately 30% of the patients develop…”
Get full text

Results of a First in Human, Dose Ascending, Phase I Study Examining the Safety and Tolerability of KA2237, an Oral PI3K p110β/δ Inhibitor in Patients with Relapsed/Refractory (R/R) B-Cell Lymphoma by Nastoupil, Loretta J., Neelapu, Sattva S, Davis, Eric, Samaniego, Felipe, Fowler, Nathan H, Westin, Jason R., Lee, Hun Ju, Wang, Michael, Hagemeister, Fredrick B., Beer, Philip, Cecil, Alexander R.L., Dow, James, McHale, Duncan, Silva, Franck, Ward, Penny, Yavari, Arash, Shuttleworth, Stephen Joseph

“…Introduction: Despite therapeutic advances, there remains a considerable need for novel therapies for B-cell lymphomas. Although a high proportion of patients…”
Get full text

Pre-Clinical Evaluation of the PI3K-p110β/δ Inhibitor KA2237 in Mantle Cell Lymphoma by Huang, Shengjian, Nastoupil, Loretta J., Guo, Hui, Bell, Taylor, Ahmed, Makhdum, Li, Carrie J, Wang, Jack, Liu, Yang, Zhang, Victoria, Kim, Caroline R, Boyle, Jordan N, Lorence, Elizabeth A, Lam, Laura T, Chen, Zhihong, Zhang, Hui, Shuttleworth, Stephen Joseph, Nomie, Krystle, Wang, Michael, Zhang, Liang

“…Background: Mantle cell lymphoma (MCL) accounts for 6% of all non-Hodgkin lymphoma and is a therapeutic challenge. Phosphoinositide-3 kinase (PI3K) has been…”
Get full text